Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
about
The Alzheimer's Prevention Clinic at Weill Cornell Medical College / New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention.A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trialsEthical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.Do Chinese Researchers Conduct Ethical Research and Use Ethics Committee Review in Clinical Trials of Anti-Dementia Drugs? An Analysis of Biomedical Publications Originating from China.Predictive testing and clinical trials in Huntington's disease: An ethical analysis.Study partners should be required in preclinical Alzheimer's disease trials.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure
P2860
Q33697647-2ABEC0A4-52DD-432B-9E4C-18A522DA68BBQ35879102-148E1E96-C81B-44FC-94EB-BE92C4E1211AQ36638757-A7B97410-6955-4F42-9923-D5F4A221EE58Q36885357-629E000A-188B-406D-B1B5-5E955701DDBBQ37561488-D4D0AA20-A312-4542-8598-41AC7CC7DA24Q38794457-D4A5A8AE-4633-4DB0-AA12-091B2E266316Q45305854-D11160C9-C5B1-4FE4-B1CD-AD14FB972383Q46028917-03AAD857-BAC2-4F35-B5EE-ADA4B75E770FQ47587631-7B8E4F2D-B32D-4574-98B9-9396C5E622D3Q50421914-BA1F0A24-12C2-4F81-93D7-6ECD1768A3D9Q56373543-59F8570B-23FA-465E-80D3-285A742308CC
P2860
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Ethics of genetic and biomarke ...... tive disease prevention trials
@ast
Ethics of genetic and biomarke ...... tive disease prevention trials
@en
type
label
Ethics of genetic and biomarke ...... tive disease prevention trials
@ast
Ethics of genetic and biomarke ...... tive disease prevention trials
@en
prefLabel
Ethics of genetic and biomarke ...... tive disease prevention trials
@ast
Ethics of genetic and biomarke ...... tive disease prevention trials
@en
P2860
P921
P1433
P1476
Ethics of genetic and biomarke ...... tive disease prevention trials
@en
P2093
Benjamin E Berkman
Scott Y H Kim
P2860
P304
P356
10.1212/WNL.0000000000001451
P407
P577
2015-03-11T00:00:00Z